文摘
The HIV protease (HIVP) is a prominent example for successful structure-based drug design. Besides itspharmaceutical impact, it is a well-studied system for which, as experimentally evidenced, protonation changesin the active site occur upon ligand binding. Therefore, it serves as an ideal candidate for a case study usingour newly developed partial charge model, which was optimized toward the application of Poisson-Boltzmannbased pKa calculations. The charge model suggests reliably experimentally determined protonation states inthe active site of HIVP. Furthermore, we perform pKa calculations for two HIVP complexes with noveltypes of inhibitors developed and synthesized in our group. For these complexes, no experimental knowledgeabout the protonation states is given. For one of the compounds, containing a central pyrrolidine ring, thecalculations predict that both catalytic aspartates should be deprotonated upon ligand binding.